B. Riley set a $19.00 price target on Catalyst Biosciences (NASDAQ:CBIO) in a research report report published on Monday morning. The firm currently has a buy rating on the biopharmaceutical company’s stock.

Separately, Zacks Investment Research upgraded Catalyst Biosciences from a hold rating to a buy rating and set a $5.25 target price on the stock in a research note on Wednesday, November 8th.

Shares of Catalyst Biosciences (NASDAQ:CBIO) opened at $12.91 on Monday. Catalyst Biosciences has a 52 week low of $3.11 and a 52 week high of $18.88.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in CBIO. Bank of New York Mellon Corp bought a new stake in shares of Catalyst Biosciences during the 2nd quarter worth $107,000. Vanguard Group Inc. raised its stake in shares of Catalyst Biosciences by 294.1% during the 2nd quarter. Vanguard Group Inc. now owns 43,714 shares of the biopharmaceutical company’s stock worth $204,000 after purchasing an additional 32,621 shares during the period. Virtu KCG Holdings LLC bought a new stake in shares of Catalyst Biosciences during the 2nd quarter worth $103,000. Dimensional Fund Advisors LP bought a new stake in shares of Catalyst Biosciences during the 2nd quarter worth $372,000. Finally, Zacks Investment Management bought a new stake in shares of Catalyst Biosciences during the 2nd quarter worth $147,000. Institutional investors own 30.96% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “B. Riley Reiterates $19.00 Price Target for Catalyst Biosciences (CBIO)” was originally reported by Watch List News and is the sole property of of Watch List News. If you are reading this piece on another website, it was stolen and republished in violation of US & international trademark & copyright laws. The correct version of this piece can be accessed at https://www.watchlistnews.com/b-riley-reiterates-19-00-price-target-for-catalyst-biosciences-cbio/1776135.html.

About Catalyst Biosciences

Catalyst Biosciences, Inc, formerly Targacept, Inc, is a clinical-stage biopharmaceutical company. The Company is focused on creating and developing medicines to address serious medical conditions. The Company focuses its product development efforts in the fields of hemostasis, including the treatment of hemophilia and surgical bleeding, and inflammation, including prevention of delayed graft function (DGF) in renal transplants and the treatment of dry age-related macular degeneration (dry AMD), a condition that can cause visual impairment or blindness.

Receive News & Ratings for Catalyst Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalyst Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.